Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial

被引：0
|
作者：
Raoul, J.
Craxi, A.
Porta, C.
Lentini, G.
Nadel, A.
Voliotis, D.
Bruix, J.
Llovet, J. M.
机构：
[1] Ctr Eugene Marquis, Rennes, France
[2] Azienda Osped Univ, Palermo, Italy
[3] San Matteo Univ Hosp, IRCCS, Pavia, Italy
[4] Bayer Vital GmbH, Leverkusen, Germany
[5] Bayer HealthCare Pharmaceut, Montville, NJ USA
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15547
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Santoro, Armando
    Ross, Paul J.
    Gane, Edward
    Vogel, Arndt
    Jeffers, Michael
    Meinhardt, Gerold
    Pena, Carol Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [43] Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
    Park, Joong-Won
    Kim, Yoon Jun
    Kim, Do Young
    Bae, Si-Hyun
    Paik, Seung Woon
    Lee, Youn-Jae
    Kim, Hwi Young
    Lee, Han Chu
    Han, Sang Young
    Cheong, Jae Youn
    Kwon, Oh Sang
    Yeon, Jong Eun
    Kim, Bo Hyun
    Hwang, Jaeseok
    JOURNAL OF HEPATOLOGY, 2019, 70 (04) : 684 - 691
  • [44] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [45] Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT)
    Siegel, A. B.
    Hsu, S. X.
    Becker, K. D.
    Anderson, S.
    Clark-Garvey, S.
    Hidalgo, R.
    Tsushima, D.
    Matushansky, I.
    Emond, J.
    Brown, R. S., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials
    Cabibbo, Giuseppe
    Cucchetti, Alessandro
    Camma, Calogero
    Casadei-Gardini, Andrea
    Celsa, Ciro
    Rizzo, Giacomo Emanuele Maria
    Johnson, Philip
    Ercolani, Giorgio
    FUTURE ONCOLOGY, 2019, 15 (29) : 3411 - 3422
  • [47] Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
    Wang, Hui
    Wang, Hefang
    Yu, Zhichong
    Liu, Honghao
    ONCOTARGETS AND THERAPY, 2018, 11 : 5195 - 5201
  • [48] Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma
    Siegel, Abby B.
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Guthrie, Katherine A.
    Goyal, Abhishek
    Venook, Alan P.
    Blanke, Charles D.
    Verna, Elizabeth C.
    Dove, Lorna
    Emond, Jean
    Kato, Tomoaki
    Samstein, Benjamin
    Busuttil, Ronald
    Remotti, Helen
    Coffey, Amy
    Brown, Robert S., Jr.
    LIVER CANCER, 2015, 4 (02) : 115 - 125
  • [49] Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
    Ciuleanu, Tudor-Eliade
    Bazin, Igor
    Lungulescu, Dan
    Miron, Lucian
    Bondarenko, Igor
    Deptala, Andrzej
    Rodriguez-Torres, Maribel
    Giantonio, Bruce J.
    Sun, Weijing
    Fox, Norma Lynn
    Aktan, Gursel
    Wissel, Paul Stephen
    Egger, Jacki
    Ding, Meichun
    Kalyani, Rubana
    Gribbin, Matthew Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
    Ohkawa, Shinichi
    Okusaka, Takuji
    Kudo, Masatoshi
    Hatano, Etsuro
    Fujii, Hirofumi
    Masumoto, Akihide
    Furuse, Junji
    Wada, Yoshiyuki
    Ishii, Hiroshi
    Obi, Shuntaro
    Arai, Kuniaki
    Kawazoe, Seiji
    Yokosuka, Osamu
    Ikeda, Masafumi
    Ukai, Katsuaki
    Morita, Sojiro
    Asou, Hiroya
    Abada, Paolo B.
    Yang, Ling
    Zhu, Andrew X.
    ANNALS OF ONCOLOGY, 2015, 26 : 94 - 94
12345